We are live on ! Find out more

Opko Health

OPK

Market cap $1.03B

1.38 USD

+0.01

0.73%

At close Updated Oct 9, 4:00 PM EDT

Pre-market

After hours

1.35

-0.03

2.17%

1 day

0.73%

5 days

-11.54%

1 month

-10.39%

3 months

-0.72%

6 months

17.95%

Year to date

8.66%

1 year

-11.54%

5 years

-63.2%

10 years

-86.13%

About: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Employees: 2,275

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 45.5%

Neutral 45.5%

Negative 9.1%

Zacks Investment Research

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

Zacks Investment Research

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

Zacks Investment Research

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

Zacks Investment Research

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

Zacks Investment Research

OPK Raises $125 Million Against Royalties: What Investors Should Know

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

OPK Raises $125 Million Against Royalties: What Investors Should Know

Zacks Investment Research

Is OPK Worth Buying as Valuation Meets Improving Business Trends?

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

Is OPK Worth Buying as Valuation Meets Improving Business Trends?

Zacks Investment Research

OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

Zacks Investment Research

OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

See News Rankings

Price charts implemented using Lightweight Charts™